Alphatec Earnings Call Highlights Growth And Margins
Alphatec ((ATEC)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alphatec’s latest earnings call painted a picture of a company in high‑growth mode with improving profitability and a deep technology pipeline. Management highlighted strong revenue and EBITDA gains, accelerating surgeon adoption, and steady margin expansion, while acknowledging modest free cash flow and some seasonal noise that may be unsettling investors in the near term.
Revenue Growth Remains Robust
Alphatec delivered Q4 2025 revenue of $213 million, up 20% year over year and $16 million sequentially. Full‑year 2025 revenue reached $764 million, a 25% increase and a $153 million jump from the prior year, underscoring sustained demand for the company’s spine solutions.
Surgical Volumes and Surgeon Adoption Accelerate
Surgical revenue rose to $190 million in Q4, up 21%, with full‑year surgical revenue climbing 26% to $687 million. Procedural volumes grew 21% in Q4 and 22% for the year, while net new surgeon users increased 23% in Q4, lifting the overall surgeon base by about 20% in 2025.
Profitability Surges on EBITDA Gains
Adjusted EBITDA in Q4 jumped 61% to $33 million, implying a 16% exit adjusted EBITDA margin for the quarter. For the full year, adjusted EBITDA reached $93 million, or 12% of sales, up $63 million and 720 basis points versus 2024 as scale benefits flowed through the income statement.
Margins Benefit From Operating Leverage
Non‑GAAP gross margin improved to about 70.5% in Q4, up 80 basis points year over year, and 70.2% for the full year. Selling, general, and administrative costs fell to roughly 55% of sales in Q4 and 59% for 2025 on a non‑GAAP basis, reflecting operating leverage from rapid revenue growth.
Solid Cash Position and Better Cash Generation
The company closed Q4 with $161 million in cash and a $60 million undrawn revolver, providing total available liquidity of $221 million. Alphatec generated $21 million of cash from operations and $8 million of free cash flow in Q4, contributing to $45 million of operating cash flow for the year.
Product Launches Expand Clinical Reach
Management highlighted a busy 2025 product cycle, including EOS Insight, a bone mineral density test, and pediatric tools that deepen imaging‑based planning. New surgical hardware such as a cervical retractor and SPS plating system, 3D‑printed implants, a corpectomy device, biologics, and a fortified SafeOp neuromonitoring platform broaden the company’s procedural toolkit.
Strategic Tech Roadmap Anchored by Valence and EOS
Alphatec’s Valence platform, combining navigation with robotically controlled precision, is slated for a controlled release in 2026. At the same time, growth in the EOS Edge installed base is driving higher implant usage, while EOS Insight remains underpenetrated, representing a meaningful long‑term growth lever.
Partnerships Deepen the Long‑Term Pipeline
The company signed an exclusive distribution deal with Theradaptive for a next‑generation bone morphogenetic protein designed for faster bone formation and a higher safety margin. Management views this as a potentially significant long‑term opportunity in the large BMP market and a way to enhance Alphatec’s biologics portfolio.
2026 Guidance Signals Continued Margin Expansion
For 2026, Alphatec guided revenue to about $890 million, up roughly 17%, with around $805 million from surgical revenue and $85 million from EOS. Management raised adjusted EBITDA guidance to $134 million, or a 15% margin, expects gross margins to approach 71% by year‑end, and projects at least $20 million of free cash flow alongside operating margin expansion of about 400 basis points.
Cash Flow and Mix Headwinds Temper the Story
Despite strong operating cash generation, full‑year 2025 free cash flow was only $3 million as Alphatec reinvested heavily in instruments and inventory. International cases and a shift toward cervical procedures weighed on average revenue per procedure, keeping ARPC flat in Q4 and creating a roughly 120 basis point headwind to per‑case revenue.
Seasonality Shift and Investor Skepticism
Growth in deformity procedures and EOS‑driven volumes made Q2 and Q3 unusually strong in 2025, reducing the typical Q4 sequential step‑up and complicating short‑term revenue cadence. Management also noted that the stock traded lower after hours despite in‑line revenue and EBITDA upside, suggesting investor concerns around seasonality and spending levels, including still‑elevated SG&A in absolute dollars.
Alphatec’s call underscored a company balancing rapid growth with disciplined margin expansion and intensive reinvestment in its platform. While free cash flow is still modest and mix‑related pressures persist, the combination of double‑digit top‑line growth, rising profitability, and a robust innovation roadmap leaves the longer‑term equity story firmly intact for investors focused beyond the next quarter.
